Antinuclear antibodies in patients receiving non-practolol beta-blockers.
Antinuclear antibodies (ANA) were found in 54 (7.0%) out of 767 treated hypertensive patients compared with 59 (2.4%) out of 2470 healthy controls. Inclusion of a non-practolol beta-blocker in the treatment regimen did not significantly affect the incidence of ANA. ANA was found in significantly more patients being treated with methyldopa (13.0%) than patients receiving other hypotensive agents (3.8%). Non-practolol beta-blockers in combination with methyldopa did not increase the incidence of ANA further.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000974:Antibodies, Antinuclear / Q000032:analysis*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000276:immunology*; D008297:Male; D008750:Methyldopa / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged
D000319:Adrenergic beta-Antagonists; D000974:Antibodies, Antinuclear; D008750:Methyldopa